Rakovina Therapeutics Initiates New Funding Strategy
Rakovina Therapeutics Inc. (TSX-V: RKV) is embarking on an exciting chapter as the biopharmaceutical company announces a private placement offering aimed at raising up to $1.25 million. This initiative reflects the company's commitment to revolutionize cancer treatment through innovative DNA-damage response technologies.
Funding Details and Investor Engagement
The company has already garnered significant interest, receiving initial commitments of over $800,000 from a variety of strategic investors. The private placement is structured as units priced at $0.06 each. Each unit comprises one common share and a warrant that allows the holder to purchase an additional common share at a price of $0.10 per share, with a 24-month exercise period. Notably, Rakovina maintains the right to accelerate the period during which warrants can be exercised if its shares' price exceeds $0.30 over a 20-day volume-weighted average.
Utilization of Funds for Research and Development
With the funds raised from this offering, Rakovina plans to further its research into novel cancer treatments. The company aims to harness its proprietary AI platforms, the Deep Docking™ AI platform and the Variational AI Enki™ Platform, to expedite the discovery and advancement of cutting-edge therapies. Additionally, there is a focus on progressing development of the kt-3000 series through strategic collaborations with various biotech and pharmaceutical companies.
Insight from Leadership
Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics, expressed his gratitude towards the investors, stating, "We are deeply grateful to our investors—both long-standing and new—whose confidence reinforces the promise of our development efforts. Our recent data demonstrates that the Deep Docking AI platform has delivered on its objective, generating a focused shortlist of potential best-in-class PARP-1 inhibitor candidates capable of crossing the blood-brain barrier. The next critical step is to validate these promising candidates using our wet-lab infrastructure at the University of British Columbia while advancing work on our next target. This financing provides the additional resources necessary to achieve these goals."
Private Placement Compliance and Resale Restrictions
The units will be sold under a non-brokered basis aligned with Canadian securities laws, ensuring compliance with applicable prospectus exemptions. It is important to note that the securities will be subject to resale restrictions for a minimum of four months and one day from the date of issuance, safeguarding both the Company and its investors.
About Rakovina Therapeutics
Rakovina Therapeutics is dedicated to innovating cancer care by developing new therapies that leverage its advanced understanding of DNA-damage repair mechanisms. The firm's mission includes driving its promising drug candidates toward human clinical trials while seeking necessary approvals from regulatory authorities such as Health Canada and the U.S. Food and Drug Administration.
Contact Information
For further details on the company's initiatives or inquiries, interested parties can reach out to David Hyman, Chief Financial Officer, via email at info@rakovinatherapeutics.com. Additional inquiries regarding investor relations and media can be directed to Michelle Seltenrich at ir@rakovinatherapeutics.com or by phone at 778-773-5432.
Frequently Asked Questions
What is the purpose of Rakovina Therapeutics' private placement?
The private placement aims to raise up to $1.25 million to advance cancer treatment research using AI technologies.
How much funding has Rakovina received so far?
So far, the company has received commitments exceeding $800,000 from various strategic investors.
What is the structure of the private placement offering?
The offering includes units priced at $0.06 each, consisting of one common share and one warrant at $0.10, exercisable for 24 months.
How will the funds be utilized by Rakovina Therapeutics?
The funds will support ongoing research and development of new cancer treatments and enhance collaboration with biotechnology partners.
Who can be contacted for more information?
David Hyman, CFO, can be contacted via email at info@rakovinatherapeutics.com for additional information.
